Pancreatic Cancer Research

ResearcherMedical University of South CarolinaNo recent work listed

Xiang Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5498-6942; OpenAlex author ID A5100408567. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 2

  1. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer. Co-author DOI 10.1016/j.ymthe.2020.12.029↗
  2. LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. Last author DOI 10.1124/jpet.112.199216↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Divya Thomas · 1 shared paper, 2021 · strength 0.10
  2. Thomas C. Caffrey · 1 shared paper, 2021 · strength 0.10
  3. H. Carlo Maurer · 1 shared paper, 2021 · strength 0.10
  4. Satish Sagar · 1 shared paper, 2021 · strength 0.10
  5. Jen Jen Yeh · 1 shared paper, 2021 · strength 0.10
  6. Michael Anthony Hollingsworth · 1 shared paper, 2021 · strength 0.10
  7. Paul M. Grandgenett · 1 shared paper, 2021 · strength 0.10
  8. Prakash Radhakrishnan · 1 shared paper, 2021 · strength 0.10
  9. Kenneth P. Olive · 1 shared paper, 2021 · strength 0.10
  10. Thomas Hendrix Beckham · 1 shared paper, 2013 · strength 0.03
  11. Clayton S. Lewis · 1 shared paper, 2013 · strength 0.03
  12. Richard R. Drake · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.